Press releasePRNewswire
Rigel Pharmaceuticals
RIGL · NASDAQ
$48.11+$1.39 (+2.98%)TodayMarket closed ·
Prev close $46.72
Latest news
- Press releasePRNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Press releasePRNewswire
Rigel to Participate in Upcoming September Investor Conferences
- Press releasePRNewswire
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate
- Press releasePRNewswire
Rigel Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
- Press releasePRNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Press releasePRNewswire
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
- Press releasePRNewswire
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
- Press releasePRNewswire
Rigel to Present at the Jefferies Global Healthcare Conference
- Press releasePRNewswire
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
- Press releasePRNewswire
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
- NewsAvi Kapoor
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
- NewsVandana Singh
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
- News
Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel
- News
Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead
- Press releasePRNewswire
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
- News
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
- News
Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate
- Press releasePRNewswire
Rigel Reports First Quarter 2026 Financial Results
- News
Earnings Scheduled For May 5, 2026
- Press releasePRNewswire
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
- Press releasePRNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Press releasePRNewswire
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Surges Over 1%; ISM Services PMI Tops Views
- News
Earnings Summary: Rigel Pharmaceuticals Q4
- News
Rigel Pharmaceuticals Q4 Adj. EPS $1.12 Misses $1.25 Estimate, Sales $69.802M Beat $68.701M Estimate
- Press releasePRNewswire
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Press releasePRNewswire
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
- Press releasePRNewswire
Rigel Appoints Michael P. Miller to the Board of Directors
- Press releasePRNewswire
Rigel Provides Business Update and 2026 Outlook
- Press releasePRNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Press releasePRNewswire
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Press releasePRNewswire
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
- Press releasePRNewswire
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.